Personalised Medicine research Centre promises to reshape the way we treat diseases
Murdoch University scientists are sharpening their focus on the development of personalised treatments for rare and inherited diseases with the...
Continue reading
This website may not work correctly in Internet Explorer. We recommend switching to a more secure modern web browser such as Microsoft Edge which is already installed on your computer.
Research group
Arpitha Chikkanna is a PhD candidate currently working on designing novel Antisense Oligonucleotides (ASOs) as a therapeutic option for chronic kidney conditions. In patients with these conditions, kidney metabolism is not as efficient as in normal individual. To elaborate on this, Arpitha is designing and fine-tuning the ASOs to target the hallmark gene of the disease. She hopes to achieve a lead candidate that can improve kidney metabolism thereby benefits the patients therapeutically.
Keep informed with our latest updates.
Stay up to date with our latest news and announcements.